DCOY — Decoy Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Sonendo, Albertsons, Netflix
Salarius Pharma drops after patient death in cancer drug study
Brief: Salarius Pauses New Patient Enrollment In Phase 1/2 Trial For Sarcomas Treatment
Brief: Salarius Pharmaceuticals Announces 1-For-25 Reverse Stock Split
Brief: Salarius Pharmaceuticals Inc Believe Planned Operations Are Funded Well Into 2023
Brief: Salarius Pharmaceuticals Adds Two Mayo Clinic Sites To Its Ongoing Phase 1/2 Trial Of Seclidemstat As Treatment For Ewing's Sarcoma And FET-Rearranged Sarcomas
Brief: Salarius Pharmaceuticals Reports 9 Cents Loss Per Share In Q2
Brief: Salarius Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Million – SEC Filing
Brief: Salarius, VolitionRx Enter Into Research, Development Collaboration Deal
Brief: Salarius Pharma Files Prospectus Related To Resale Of Up To 7 Million Shares By Selling Stockholders
Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Salarius Pharmaceuticals Completes SP-3164 Pre-IND Meeting Process With FDA
Salarius Pharmaceuticals Inc expected to post a loss of 9 cents a share - Earnings Preview
Salarius Pharmaceuticals Inc expected to post a loss of 9 cents a share - Earnings Preview
Salarius Pharma slumps as higher costs drive bigger loss, PT cut
Salarius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Salarius Pharmaceuticals Reports Business Highlights With Fourth Quarter And Full-Year 2021 Financial Results
Salarius Pharmaceuticals Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Salarius Pharmaceuticals Appoints Daniela Santiesteban To Director Of Targeted Protein Degradation Program